Avicella Capital

Convergence Medical Robotics is a Brisbane-based pre-clinical medical robotics company making arthroscopy better through the invention of the V01 Robot. It solves the complexity of arthroscopy by creating the world's first arthroscopic robot.

Kinoxis Therapeutics is an early-stage Australian biotechnology company focused on developing novel therapeutics for substance use disorders and other central nervous system conditions. It licenses its compounds from the University of Sydney. Its lead candidate has shown potent anti-addictive and prosocial effects in multiple animal models and is advancing through preclinical testing. The company is also developing KNX100, described as a first-in-class treatment for agitation in dementia and substance use disorders through a novel mechanism intended to modulate dysregulated brain systems and provide safe, effective therapy.